ClinicaliQ Trial Snapshot
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) — Recruiting • Phase II • Oncology • NCT06667908.
- What is being tested: JNJ-90301900 (an investigational immunotherapy agent) combined with standard concurrent platinum-based chemotherapy and radiation therapy, followed by consolidation immunotherapy, to determine if this combination improves objective response rates in NSCLC patients compared to standard treatment alone.
- Patient eligibility overview: The trial recruits patients with non-small cell lung cancer suitable for concurrent chemoradiation therapy; specific stage and performance status criteria apply (full eligibility requires review of detailed protocol).
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Eligibility Snapshot
- : * Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening * Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization * Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification * Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.